海珠益肝方加减治疗乙肝肝纤维化的临床研究

Clinical Study on Treatment of Hepatitis B Hepatic Fibrosis with Haizhu Yigan Decoction

目的:探究海珠益肝方加减治疗乙肝肝纤维化的临床效果。方法:选取2016年9月-2017年6月本院收治的乙肝肝纤维化患者126例,按照随机数字表法分为研究组和常规组,各63例。对常规组采用恩替卡韦片治疗,研究组患者采用恩替卡韦片联合海珠益肝方治疗。比较两组治疗效果、肝功能、肝纤维化指标及影像学检测结果。结果:研究组治疗总有效率为88.89%,优于常规组的60.32%(P<0.05);治疗后,两组肝功能、肝纤维化指标均优于治疗前,且研究组均优于常规组,比较差异均有统计学意义(P<0.05);治疗后,两组门静脉内径、脾厚均低于治疗前,且研究组均低于常规组,比较差异均有统计学意义(P<0.05),研究组肝实质回声欠均匀患者由治疗前的40例降低至29例(P<0.05)。结论:对乙肝肝纤维化患者采用恩替卡韦片联合海珠益肝方进行治疗,能够显著提高治疗效果,改善其肝功能,降低其肝纤维化水平,对提高患者生活质量具有重要意义。

Objective:To explore the clinical effect of Haizhu Yigan Decoction in treatment of hepatitis B liver fibrosis.Method:A total of 126 patients with hepatitis B fibrosis admitted to our hospital from September 2016 to June 2017 were selected.The patients were randomly divided into study group and routine group,63 cases in each group.The routine group was treated with Entecavir Tablets,while study group was treated with Entecavir Tablets combined with Haizhu Yigan Decoction.The therapeutic effect,liver function,liver fibrosis index and imaging results between two groups were compared.Result:The total effective rate of study group was 88.89%,which was better than 60.32% of routine group(P<0.05).After treatment,the liver function and liver fibrosis indexes of two groups were better than those of before treatment,and the study group were better than those of routine group,the differences were statistically significant(P<0.05).After treatment,the diameter of portal vein and spleen thickness of two groups were lower than those of before treatment,and study group were lower than those of routine group,the differences were statistically significant (P<0.05),and the hypoechoic liver parenchyma decreased from 40 cases before treatment to 29 cases in study group(P<0.05).Conclusion:Entecavir Tablets combined with Haizhu Yigan Decoction can significantly improve the therapeutic effect,improve the liver function and reduce the level of hepatic fibrosis in patients with hepatitis B fibrosis,which is of great significance to improve the quality of life of patients.